16-chlorohexadecanol | 73937-06-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 16-chlorohexadecanol
• 英文别名: 16-chloro-hexadecan-1-ol；16-Chlor-hexadecan-1-ol；16-Chlorohexadecan-1-ol
• CAS: 73937-06-1
• 化学式: C₁₆H₃₃ClO
• 分子量: 276.89
• InChiKey: KJSMOEAZOWUDEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  18
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  16-chlorohexadecanol 在 三氟化硼乙醚 、 potassium carbonate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 3-O-benzyl-1-O-(16-chlorohexadecyl)-sn-glycerol
  参考文献：
  名称：

  A new approach to archaebacterial lipid models

  摘要：

  1,1'-(alpha,omega-Alkylidene)-2,2'-dialkylglycerol tetraether lipid models (9) have been prepared by coupling two equivalents of 1-(omega-haloalkyl)-2-alkylglycerol diethers, through silver-catalyzed coupling of the Grignard reagents 8 with iodide 7.

  DOI：

  10.1016/s0040-4039(00)79333-6
• 作为产物：
  描述：

  1,16-十六烷二醇 在 氯化亚砜 、 2,3-二甲基苯胺 、 苯 作用下， 生成 1,16-dichloro-hexadecane 、 16-chlorohexadecanol
  参考文献：
  名称：

  135.脂族二醇的衍生物。第四部分

  摘要：

  DOI：

  10.1039/jr9380001679

文献信息

• [EN] ANTIMICROBIAL AGENT, COATING FORMULATION, COMPOSITE SURFACE COATING AND METHODS OF PREPARING THE SAME<br/>[FR] AGENT ANTIMICROBIEN, FORMULATION DE REVÊTEMENT, REVÊTEMENT DE SURFACE COMPOSITE ET LEURS PROCÉDÉS DE PRÉPARATION
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2021107870A1

  公开（公告）日：2021-06-03

  There is provided an antimicrobial agent comprising at least one polymer comprising an optionally substituted heteroaryl amine salt moiety such as an imidazolium salt or an optionally substituted quaternary ammonium cation moiety. The polymer has terminal hydroxyl groups. A coating formulation comprising at least one sol-gel precursor and said antimicrobial agent, as well as a composite surface coating comprising said antimicrobial agent are also provided. Further provided are methods of preparing the antimicrobial agent, composite surface coating and use of the composite surface coating for antimicrobial applications.

  提供一种抗微生物剂，包括至少一种聚合物，其中该聚合物包含一个可选择取代的杂环胺盐基团，例如咪唑盐或可选择取代的季铵阳离子基团。该聚合物具有末端羟基。还提供一种包含至少一种溶胶-凝胶前体和该抗微生物剂的涂层配方，以及包含该抗微生物剂的复合表面涂层。还提供了制备抗微生物剂、复合表面涂层以及使用该复合表面涂层进行抗微生物应用的方法。
• Emulsion with discontinouous phase including particle sol
  申请人：Harding Phil

  公开号：US20050227096A1

  公开（公告）日：2005-10-13

  A composition of matter includes an emulsion with a discontinuous phase of particle sol.

  物质组合物包括带有颗粒溶胶不连续相的乳液。
• Familial Head and Neck Cancer: Molecular Analysis of a New Clinical Entity
  作者：Kathy K. Yu、Adam M. Zanation、Jonathan R. Moss、Wendell G. Yarbrough

  DOI：10.1097/00005537-200209000-00010

  日期：2002.9

  AbstractObjective The tumor suppressor gene p16 encodes a cyclin‐dependent kinase inhibitor that normally inhibits cell proliferation by causing a G1 cell cycle arrest. The p16 gene is frequently mutated in a variety of somatic tumors, as well as in familial melanoma and familial pancreatic carcinoma. We identified a family with a high incidence of head and neck squamous cell carcinoma (HNSCC) and melanoma. Molecular analyses of the p16 gene locus in blood and tumor DNA from this family was performed to determine whether an association between germline p16 gene mutation and HNSCC exists.Study Design Molecular pedigree analyses.Methods Exon 2 of p16 was polymerase chain reaction amplified from blood, tumor, or nontumor DNA isolated from affected and unaffected members, then directly sequenced and compared with consensus p16 sequence. Cell cycle position of cells expressing wild‐type or mutant p16 was determined by flow cytometry.Results Molecular analyses revealed a nonfunctional germline point mutation within exon 2 of the p16 gene that encodes a mutant p16 protein substituting proline at amino acid position 87 for the wild‐type arginine (p16R87P). Relative to wild‐type p16, p16R87P lost ability to cause a growth arrest following ectopic expression. The mutant (p16R87P) allele segregated with cancer predisposition in tested family members, and analyses of HNSCC tumor tissues demonstrated universal loss of wild‐type allele.Conclusions Significance of the mutant p16 (p16R87P) in HNSCC tumorigenesis is strongly suggested by its loss of cell cycle arrest activity and its retention in tumor tissue with simultaneous loss of the wild‐type allele. Further, the germline p16 mutation segregated with cancer predisposition within the family. In aggregate, these data suggest that there is a direct causal relationship between the germline p16 mutation in this family and HNSCC tumorigenesis. Based on our observations, the spectrum of familial cancers associated with p16 mutations should include a new clinical entity, familial HNSCC.
• Hydroxyalkylcysteine derivative and expectorant containing the same
  申请人：SS PHARMACEUTICAL CO., LTD.

  公开号：EP0346882B1

  公开（公告）日：1993-09-29
• DRUG DELIVERY FROM IMPLANTS USING SELF-ASSEMBLED MONOLAYERS-THERAPEUTIC SAMS
  申请人：Agrawal C. Mauli

  公开号：US20090123516A1

  公开（公告）日：2009-05-14

  Disclosed are medical devices comprising one or more surfaces, one or more SAM molecules attached to the one or more surfaces of the medical device, and one or more therapeutic agents attached to the one or more self-assembled monolayer molecules. Also disclosed are medical devices comprising one or more surfaces, one or more self-assembled monolayer molecules attached to the one or more surfaces of the medical device, one or more linkers comprising a first functional group and a second functional group, the first functional group attached to the self-assembled monolayer molecule and a therapeutic agent attached to the second functional group. The therapeutic agent may be attached to the SAM molecule via a linker. The present invention also concerns methods of administering a therapeutic agent to a subject, comprising contacting the subject with one of the medical devices set forth herein.